Sanofi pours $1 billion into China for insulin plant

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Lots on the table today about AI-driven drug discovery, including some startups to watch in this space. Also, we’ve updated our obesity drug tracker and we talk about Gilead’s new cancer deal.

The need-to-know this morning

• Shares of Janux Therapeutics rose sharply after the company reported better-than-expected results from an early study of its experimental treatment for prostate cancer.
• Takeda is paying $200 million upfront to license an experimental drug from Keros Therapeutics in development for myelodysplastic syndrome and myelofibrosis.
• Roivant is discontinuing the development of a drug for the lung disease sarcoidosis following negative results from a mid-stage clinical trial.

Moving forward with AI and drug discovery

The hype bubble of AI-driven drug discovery is getting a little precarious. We recently saw Insilico Medicine fall short on statistically significant efficacy with its AI-designed drug, and Recursion Pharmaceuticals showed no reportable efficacy with its own AI-discovered therapy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In